Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Malley Thomas, holds the title of Director at Kura Oncology, Inc..
On 2026-06-04, the insider transacted 35,000 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
**Transaction:** grant of 35,000 shares by Malley Thomas (Director). **Strategic Implications (Investor Edge):** This grant is a routine compensation event and provides no actionable signal about the director's conviction or the company's near-term prospects. It does not indicate bullish or bearish sentiment. **Key Takeaways:** - Transaction type is a grant, not an open market purchase or sale. - No cash was exchanged; shares were awarded as compensation. - This filing is neutral and does not warrant any trading action.
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.